Therapeutic area intelligence for Nicotine Replacement Therapy with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Dr. Reddy's Labs →

Assets

FDA →

Recent signals(2)

StrategyAugust 7, 2026

FDA Approval Process for Nicotine Polacrilex by Dr. Reddy's Labs

Reddy's Labs has submitted an application for Nicotine Polacrilex under ANDA215276, currently in the approval process.

CompetitiveJuly 14, 2026

FDA Grants AP Status for Nicotine Polacrilex by Dr. Reddy's Labs

The FDA has granted Abbreviated Approval (AP) status for ANDA215276, a nicotine polacrilex product from Dr. Reddy's Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.